ad6548b723
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
- Source: inbox/queue/2026-04-24-arpa-h-evident-139m-behavioral-health-psychedelics.md - Domain: health - Claims: 0, Entities: 4 - Enrichments: 3 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
38 lines
No EOL
2.3 KiB
Markdown
38 lines
No EOL
2.3 KiB
Markdown
# Texas IMPACT Consortium
|
|
|
|
**Full name:** Texas Ibogaine Multi-site Program for Addiction and Combat Trauma (IMPACT)
|
|
|
|
**Location:** Texas
|
|
|
|
**Total funding:** ~$100 million ($50M state + $50M ARPA-H federal match)
|
|
|
|
**Focus:** Ibogaine research for addiction and combat-related trauma in veteran populations
|
|
|
|
## Funding Structure
|
|
|
|
**State investment:** $50 million from Texas state government
|
|
|
|
**Federal match:** $50 million from ARPA-H EVIDENT initiative, implementing Trump April 18, 2026 Executive Order matching mechanism
|
|
|
|
**Total:** ~$100 million—largest single psychedelic research investment to date
|
|
|
|
## Strategic Context
|
|
|
|
**Political constituency:** Veteran-focused research transcends partisan politics, enabling conservative state (Texas) to lead psychedelic research investment. Veteran constituency provides political cover for Schedule I substance research.
|
|
|
|
**Evidence base:** Funding allocated before Phase 3 completion, based primarily on Stanford n=30 pilot study, illustrating constituency-driven acceleration ahead of traditional evidence hierarchy.
|
|
|
|
**Indication focus:** Opioid use disorder (OUD) and combat-related PTSD in veteran populations
|
|
|
|
## Timeline
|
|
|
|
- **2026-04-18** — Trump Executive Order directs ARPA-H to match state psychedelic research investments
|
|
- **2026-04-24** — Texas IMPACT consortium funding confirmed: $50M state + $50M ARPA-H federal match
|
|
|
|
## Analysis
|
|
|
|
The $100M total funding represents the largest single psychedelic research investment in history, exceeding all prior private pharmaceutical and philanthropic investments in individual psychedelic programs. The funding level—allocated before Phase 3 completion—demonstrates that veteran constituency political priority is overriding traditional evidence hierarchy requirements.
|
|
|
|
Texas as the lead state is strategically significant: conservative state leadership in psychedelic research signals bipartisan political viability when framed through veteran healthcare rather than counterculture associations.
|
|
|
|
Ibogaine's cardiac safety concerns (QT prolongation, arrhythmia risk) remain the primary regulatory barrier. The IMPACT consortium funding likely includes cardiac safety protocol development (IV magnesium co-administration, continuous monitoring) to address FDA approval pathway requirements. |